The Phase III Randomized Evaluation of CED of IL13-PE compared to Gliadel Wafer (GW) with Survival Endpoint Trial, known as the PRECISE Trial, in patients with initial recurrence of GBM has recently been completed. The gene discussed is IL13; the disease is glioblastoma.